SG163545A1 - 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses - Google Patents

3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Info

Publication number: SG163545A1
Authority: SG; Singapore
Prior art keywords: treatment; compound; substituted; synaptic responses; glutamatergic synaptic
Prior art date: 2007-01-03

Application number

SG201004695-1A

Other languages

English (en)

Inventor

Alexis Cordi

Gary Rogers

Rudolf Mueller

Original Assignee

Servier Lab

Cortex Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-03

Filing date

2007-12-28

Publication date

2010-08-30

2007-12-28 Application filed by Servier Lab, Cortex Pharma Inc filed Critical Servier Lab

2010-08-30 Publication of SG163545A1 publication Critical patent/SG163545A1/en

Links

-1 3-substituted-[1,2,3]-benzotriazinone compound Chemical class 0.000 title 1
230000002708 enhancing effect Effects 0.000 title 1
230000000848 glutamatergic effect Effects 0.000 title 1
230000009782 synaptic response Effects 0.000 title 1
210000004556 brain Anatomy 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 2
206010012289 Dementia Diseases 0.000 abstract 1
208000019022 Mood disease Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
230000006399 behavior Effects 0.000 abstract 1
230000002490 cerebral effect Effects 0.000 abstract 1
230000003930 cognitive ability Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
206010027175 memory impairment Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000001537 neural effect Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
210000000225 synapse Anatomy 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

SG201004695-1A 2007-01-03 2007-12-28 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses SG163545A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US87850307P	2007-01-03	2007-01-03
US92143307P	2007-04-02	2007-04-02

Publications (1)

Publication Number	Publication Date
SG163545A1 true SG163545A1 (en)	2010-08-30

Family

ID=39608956

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG201004695-1A SG163545A1 (en)	2007-01-03	2007-12-28	3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Country Status (37)

Country	Link
US (1)	US8173644B2 (sr)
EP (1)	EP2144506B1 (sr)
JP (1)	JP5139446B2 (sr)
CN (1)	CN101616592B (sr)
AP (1)	AP2502A (sr)
AR (1)	AR064740A1 (sr)
AT (1)	ATE527269T1 (sr)
AU (1)	AU2007342365B2 (sr)
BR (1)	BRPI0720749A2 (sr)
CA (1)	CA2674460C (sr)
CR (1)	CR10906A (sr)
CU (1)	CU23804B7 (sr)
CY (1)	CY1112493T1 (sr)
DK (1)	DK2144506T3 (sr)
EA (1)	EA017437B1 (sr)
EC (1)	ECSP099499A (sr)
ES (1)	ES2374995T3 (sr)
GE (1)	GEP20125438B (sr)
GT (1)	GT200900189A (sr)
HN (1)	HN2009001268A (sr)
HR (1)	HRP20110970T1 (sr)
IL (1)	IL199651A (sr)
MA (1)	MA31160B1 (sr)
ME (1)	ME00819B (sr)
MX (1)	MX2009007242A (sr)
MY (1)	MY154877A (sr)
NI (1)	NI200900131A (sr)
NZ (1)	NZ578293A (sr)
PL (1)	PL2144506T3 (sr)
PT (1)	PT2144506E (sr)
RS (1)	RS52108B (sr)
SG (1)	SG163545A1 (sr)
SI (1)	SI2144506T1 (sr)
SV (1)	SV2009003322A (sr)
TN (1)	TN2009000277A1 (sr)
WO (1)	WO2008085506A1 (sr)
ZA (1)	ZA200904826B (sr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0720323A2 (pt) *	2007-01-03	2016-08-09	Cortex Pharma Inc	composto, método de tratamento, composição farmacêutica e uso do composto
WO2008143963A1 (en)	2007-05-17	2008-11-27	Cortex Pharmaceuticals, Inc.	Di-substituted amides for enhancing glutamatergic synaptic responses
CA2695742C (en)	2007-08-10	2012-11-27	Rudolf Mueller	Bicyclic amides for enhancing glutamatergic synaptic responses
US8119632B2 (en)	2007-08-10	2012-02-21	Cortex Pharmaceuticals, Inc.	Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US20110257186A1 (en) *	2010-04-15	2011-10-20	Staubli Ursula V	Compositions and methods for treating visual disorders
WO2013075624A1 (zh)	2011-11-22	2013-05-30	北京哈三联科技股份有限公司	甘氨酸重摄取抑制剂及其应用
FR3019464B1 (fr) *	2014-04-07	2016-05-06	Servier Lab	Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
FR3034019B1 (fr) *	2015-03-26	2017-03-17	Servier Lab	Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
TN2017000508A1 (en) *	2015-06-26	2019-04-12	Takeda Pharmaceuticals Co	2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
EP3436021A4 (en)	2016-03-29	2019-11-06	RespireRx Pharmaceuticals Inc.	COMPOSITIONS AND METHODS FOR TREATING ATTENTION DEFICIT DISORDER
CN106226509B (zh) *	2016-08-12	2019-09-06	中国人民解放军第四军医大学	一种在小鼠前扣带回皮层诱发dse现象的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3723436A (en)	1971-02-25	1973-03-27	Sun Oil Co	Process for aromatic lactams
DK623586A (da) *	1985-12-27	1987-06-28	Eisai Co Ltd	Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FR2597103B1 (fr)	1986-04-15	1988-12-16	Provesan Sa	Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
EP0651746B1 (en)	1992-07-24	2002-03-27	The Regents of the University of California	Drugs that enhance synaptic responses mediated by ampa receptors
US5962477A (en) *	1994-04-12	1999-10-05	Adolor Corporation	Screening methods for cytokine inhibitors
ATE174915T1 (de) *	1994-10-31	1999-01-15	Merck Patent Gmbh	Benzylpiperidinderivate mit hoher affinität zu bindungsstellen von aminosäure-rezeptoren
US5650409A (en)	1995-06-02	1997-07-22	Cortex Pharmaceuticals, Inc.	Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en)	1996-04-03	1998-04-07	The Regents Of The University Of California	Benzoxazines for enhancing synaptic response
US6030968A (en)	1996-09-17	2000-02-29	The Regents Of The University Of California	Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en)	1997-02-13	2000-08-29	The Regents Of The University Of California	Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) *	1997-12-24	1999-11-16	Cortex Pharmaceuticals, Inc.	Benzoxazine compounds for enhancing synaptic response
IL137720A0 (en)	1998-02-18	2001-10-31	Neurosearch As	Compounds and their use as positive ampa receptor modulators
US6713474B2 (en)	1998-09-18	2004-03-30	Abbott Gmbh & Co. Kg	Pyrrolopyrimidines as therapeutic agents
US6303542B1 (en) *	2000-08-18	2001-10-16	Rohm And Haas Company	Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
US7799913B2 (en) *	2001-11-26	2010-09-21	Cortex Pharmaceuticals, Inc.	Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
JP2003238555A (ja) *	2002-02-20	2003-08-27	Sumitomo Pharmaceut Co Ltd	細胞死抑制剤
AUPS255202A0 (en)	2002-05-27	2002-06-13	Monash University	Agents and methods for the treatment of disorders associated with motor neuron degeneration
KR20050094840A (ko) *	2003-01-13	2005-09-28	코텍스 파마슈티칼스, 인크.	수면 부족 및 스트레스로 인한 인식 저하의 치료방법
GB0317482D0 (en)	2003-07-25	2003-08-27	Pfizer Ltd	Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh)	2003-10-14	2007-01-17	惠氏公司	稠合芳基和杂芳基衍生物及其使用方法
BRPI0720323A2 (pt)	2007-01-03	2016-08-09	Cortex Pharma Inc	composto, método de tratamento, composição farmacêutica e uso do composto
WO2008143963A1 (en)	2007-05-17	2008-11-27	Cortex Pharmaceuticals, Inc.	Di-substituted amides for enhancing glutamatergic synaptic responses
CA2695742C (en)	2007-08-10	2012-11-27	Rudolf Mueller	Bicyclic amides for enhancing glutamatergic synaptic responses
KR20100063087A (ko)	2007-09-20	2010-06-10	코텍스 파마슈티칼스, 인크.	글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논

2007
- 2007-12-28 GE GEAP200711384A patent/GEP20125438B/en unknown
- 2007-12-28 BR BRPI0720749-2A patent/BRPI0720749A2/pt not_active Application Discontinuation
- 2007-12-28 SG SG201004695-1A patent/SG163545A1/en unknown
- 2007-12-28 RS RS20110587A patent/RS52108B/sr unknown
- 2007-12-28 WO PCT/US2007/026416 patent/WO2008085506A1/en not_active Ceased
- 2007-12-28 MX MX2009007242A patent/MX2009007242A/es active IP Right Grant
- 2007-12-28 ES ES07868093T patent/ES2374995T3/es active Active
- 2007-12-28 AT AT07868093T patent/ATE527269T1/de active
- 2007-12-28 US US12/448,784 patent/US8173644B2/en not_active Expired - Fee Related
- 2007-12-28 EA EA200900925A patent/EA017437B1/ru not_active IP Right Cessation
- 2007-12-28 EP EP07868093A patent/EP2144506B1/en active Active
- 2007-12-28 NZ NZ578293A patent/NZ578293A/en not_active IP Right Cessation
- 2007-12-28 DK DK07868093.1T patent/DK2144506T3/da active
- 2007-12-28 PT PT07868093T patent/PT2144506E/pt unknown
- 2007-12-28 PL PL07868093T patent/PL2144506T3/pl unknown
- 2007-12-28 ME MEP-2009-238A patent/ME00819B/me unknown
- 2007-12-28 ZA ZA200904826A patent/ZA200904826B/xx unknown
- 2007-12-28 SI SI200730806T patent/SI2144506T1/sl unknown
- 2007-12-28 AP AP2009004931A patent/AP2502A/xx active
- 2007-12-28 CA CA2674460A patent/CA2674460C/en not_active Expired - Fee Related
- 2007-12-28 AU AU2007342365A patent/AU2007342365B2/en not_active Ceased
- 2007-12-28 MY MYPI20092796A patent/MY154877A/en unknown
- 2007-12-28 CN CN2007800508375A patent/CN101616592B/zh not_active Expired - Fee Related
- 2007-12-28 HR HR20110970T patent/HRP20110970T1/hr unknown
- 2007-12-28 JP JP2009544857A patent/JP5139446B2/ja not_active Expired - Fee Related
2008
- 2008-01-03 AR ARP080100022A patent/AR064740A1/es not_active Application Discontinuation
2009
- 2009-06-30 TN TNP2009000277A patent/TN2009000277A1/fr unknown
- 2009-07-01 NI NI200900131A patent/NI200900131A/es unknown
- 2009-07-02 SV SV2009003322A patent/SV2009003322A/es unknown
- 2009-07-02 GT GT200900189A patent/GT200900189A/es unknown
- 2009-07-02 CR CR10906A patent/CR10906A/es not_active Application Discontinuation
- 2009-07-02 IL IL199651A patent/IL199651A/en active IP Right Grant
- 2009-07-03 HN HN2009001268A patent/HN2009001268A/es unknown
- 2009-07-03 CU CU20090117A patent/CU23804B7/es active IP Right Grant
- 2009-07-07 EC EC2009009499A patent/ECSP099499A/es unknown
- 2009-07-31 MA MA32135A patent/MA31160B1/fr unknown
2011
- 2011-12-28 CY CY20111101287T patent/CY1112493T1/el unknown

Also Published As

Publication number	Publication date
ZA200904826B (en)	2010-09-29
TN2009000277A1 (en)	2010-10-18
AU2007342365A1 (en)	2008-07-17
GEP20125438B (en)	2012-03-26
EP2144506A4 (en)	2010-05-05
MY154877A (en)	2015-08-14
JP5139446B2 (ja)	2013-02-06
EP2144506B1 (en)	2011-10-05
CN101616592A (zh)	2009-12-30
EA017437B1 (ru)	2012-12-28
AP2009004931A0 (en)	2009-08-31
AR064740A1 (es)	2009-04-22
NI200900131A (es)	2010-03-11
GT200900189A (es)	2011-08-02
EA200900925A1 (ru)	2009-12-30
SI2144506T1 (sl)	2012-01-31
CU23804B7 (es)	2012-03-15
AU2007342365B2 (en)	2012-11-15
ATE527269T1 (de)	2011-10-15
PT2144506E (pt)	2011-12-21
IL199651A0 (en)	2010-04-15
US8173644B2 (en)	2012-05-08
ES2374995T3 (es)	2012-02-23
ME00819B (me)	2012-03-20
CN101616592B (zh)	2013-06-05
DK2144506T3 (da)	2012-03-05
CY1112493T1 (el)	2015-12-09
HN2009001268A (es)	2011-12-27
RS52108B (sr)	2012-08-31
JP2010514838A (ja)	2010-05-06
MA31160B1 (fr)	2010-02-01
ECSP099499A (es)	2009-10-30
MX2009007242A (es)	2009-09-02
WO2008085506A1 (en)	2008-07-17
CA2674460C (en)	2014-07-15
PL2144506T3 (pl)	2012-04-30
CA2674460A1 (en)	2008-07-17
AP2502A (en)	2012-10-23
IL199651A (en)	2015-08-31
CU20090117A7 (es)	2011-10-05
NZ578293A (en)	2012-01-12
US20100137295A1 (en)	2010-06-03
CR10906A (es)	2009-10-23
EP2144506A1 (en)	2010-01-20
BRPI0720749A2 (pt)	2014-01-14
SV2009003322A (es)	2010-02-05
HK1140105A1 (en)	2010-10-08
HRP20110970T1 (hr)	2012-01-31

Publication	Publication Date	Title
SG163545A1 (en)	2010-08-30	3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
TN2009000278A1 (en)	2010-10-18	3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
Cantone et al.	2014	The contribution of transcranial magnetic stimulation in the diagnosis and in the management of dementia
EA201390971A1 (ru)	2014-02-28	ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
BRPI0817271A2 (pt)	2015-06-16	Método de tratamento da doença de parkinson e outros distúrbios relacionados
EP2340242A4 (en)	2012-04-04	COMPOUNDS FOR THE TREATMENT OF EYE DISEASES AND DRESSES
MY148558A (en)	2013-04-30	Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
WO2013025997A3 (en)	2013-05-10	Brain stimulation methods for treating central sensitivity
EA201071243A1 (ru)	2011-06-30	Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
WO2008050341A3 (en)	2008-06-19	Novel psychotropic agents having glutamate nmda activity
WO2008148801A8 (en)	2009-12-10	Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
EP2152865A4 (en)	2010-11-03	METHOD FOR THE TREATMENT AND PREVENTION OF NEURODEEGENERATIVE DISEASES AND DISORDERS
WO2013029060A3 (en)	2014-05-08	Compositions and methods for treating neurodegenerative disease
EP2750606A4 (en)	2015-04-29	METHOD FOR THE DIAGNOSIS AND TREATMENT OF NEUROLOGICAL AND NEURODEEGENERATIVE DISEASES, DISORDERS AND RELATED METHODS
JP2009537568A5 (sr)	2010-07-01
WO2003045315A3 (en)	2003-08-28	Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
UA93306C2 (ru)	2011-01-25	Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций
EP2566856A4 (en)	2013-11-20	COMPOUNDS AND METHOD FOR TREATING BRAIN DISEASES
EP2552473A4 (en)	2013-10-23	METHOD FOR THE TREATMENT OF MORBUS PARKINSON AND OTHER DISORDERS OF DOPAMINERGIC NEURONS OF THE BRAIN
WO2011015646A3 (en)	2011-03-31	Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
WO2010087981A3 (en)	2011-03-24	Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
HK1140209A1 (en)	2010-10-08	Receptor modulators exhibiting neuroprotective and memory enhancing activities
HK1148234A (en)	2011-09-02	Device and method for treating central nervous system pathology
HK1173654A1 (zh)	2013-05-24	治疗化合物及相关的使用方法